Our translational research is aimed at improving early diagnostics and therapies for chronic lung diseases (CLDs) including progressive pulmonary fibrosis, chronic obstructive pulmonary disease and asthma. An overarching trigger for these diseases is the airborne exposome, i.e. all inhaled environmental exposures from conception onwards, although the exact underlying pathogenic mechanisms are unclear. 

Our research investigates the cellular and molecular mechanisms underlying exposome-induced CLDs with a special focus on inflammation and redox signaling. We use advanced respiratory human in vitro and ex vivo models as well as animal studies to examine and modulate these processes in relation to CLDs. Within these models, we focus on molecular and biochemical analysis of redox and inflammatory markers to select a panel of biomarkers for diagnosing and monitoring CLDs and the efficacy of their treatments. The most prominent markers deriving from these studies are additionally analyzed in human samples of healthy individuals and CLD patients in national longitudinal cohorts and biobank samples from our clinical collaborators. 

With this interdisciplinary approach, we aim to bridge the gap between laboratory research and clinical applications to ultimately enhance early diagnostic and therapeutic strategies to prevent CLDs and their progression.  

Lead scientist

Agnes Boots